Funding for this research was provided by:
Bill & Melinda Gates Foundation (INV-008166)
Received: 23 December 2020
Accepted: 21 April 2021
First Online: 2 June 2021
: The GBD study used de-identified data, and the waiver of informed consent was reviewed and approved by the University of Washington Institutional Review Board (application number 46665).
: Not applicable.
: Dr. Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Adept Field solutions, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology, personal fees from Simply Speaking, ownership in stock options from Amarin, Viking, Moderna, Vaxart pharmaceuticals, and Charlotte’s Web Holdings, non-financial support from FDA Arthritis Advisory Committee, non-financial support from Steering committee of OMERACT, an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies, non-financial support from Veterans Affairs Rheumatology Field Advisory Committee, non-financial support from Editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis, outside the submitted work.